MICA

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Friday, March 1, 2024

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-619 in relapsed/refractory multiple myeloma. CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to stress-induced ligands, MICA and MICB, which are expressed on a wide variety of solid tumors and hematologic malignancies. The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.

Key Points: 
  • The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.
  • “Multiple myeloma remains incurable, and most patients experience sequential relapses.
  • The response to treatment is typically shorter with each relapse, so novel treatments are still needed,” said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Oncology.
  • “Multiple myeloma is another example of a malignancy where MICA/B shedding from tumor cells allows for immune evasion.

$15 Million Dividend Declared by Mutual Insurance Company of Arizona

Retrieved on: 
Friday, January 5, 2024

PHOENIX, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The Mutual Insurance Company of Arizona® (MICA) announced today that its Board of Trustees has declared a dividend to its policyholders.

Key Points: 
  • PHOENIX, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The Mutual Insurance Company of Arizona® (MICA) announced today that its Board of Trustees has declared a dividend to its policyholders.
  • A total of $15 million will be allocated among current members as of December 31, 2023, the record date.
  • This dividend will be distributed in February 2024.
  • Additional information regarding the policyholder dividend distribution for each member will be available on the member portal at www.mica-insurance.com in early February 2024.

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Retrieved on: 
Friday, November 3, 2023

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting taking place November 1-5 in San Diego.

Key Points: 
  • “We are proud to showcase progress of our diversified pipeline at SITC 2023, where we will present data across multiple targets, mechanisms, and modalities,” said Jennifer Michaelson, Ph.D., Chief Scientific Officer of Cullinan Oncology.
  • Data from patients with available biopsy data demonstrate clinical benefit, including objective response, in patients with tumors with characteristics not typically responsive to checkpoint inhibitor therapy.
  • Specifically, tumors from two patients with endometrial cancer and previously reported confirmed partial responses were microsatellite stable (MSS), had low tumor mutational burden, and low neoantigen presentation index.
  • Available biopsies from patients with prolonged stable disease showed similar low mutational burden and neoantigen presentation index characteristics, as well as increased surface MICA/B expression and NK cell activation.

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Retrieved on: 
Friday, November 3, 2023

We are also developing additional CD3 and CD28 T cell engaging bispecific antibodies against solid tumor targets.”

Key Points: 
  • We are also developing additional CD3 and CD28 T cell engaging bispecific antibodies against solid tumor targets.”
    Posters will be available in the poster hall and virtually to registrants of the SITC Annual Meeting.
  • In the poster hall, odd-numbered posters will be displayed on Friday, November 3, and even-numbered posters will be displayed on Saturday, November 4.
  • Xencor’s posters will be archived under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • To enhance the anti-tumor activity, Xencor engineered multi-specific NK cell-engaging antibodies that simultaneously target MICA/B antigens and an orthogonal activating receptor on NK cells, NKp46.

Mica Market to grow by USD 97.85 million from 2022 to 2027 | Aromax Colourants Pvt. Ltd., Asheville Mica Co., BASF SE, and more among key companies- Technavio

Retrieved on: 
Tuesday, October 17, 2023

NEW YORK, Oct. 16, 2023 /PRNewswire/ -- The mica market is expected to grow by USD 97.85 million from 2022 to 2027.

Key Points: 
  • NEW YORK, Oct. 16, 2023 /PRNewswire/ -- The mica market is expected to grow by USD 97.85 million from 2022 to 2027.
  • However, factors such as stringent regulations and policies in the global mica market may impede market growth.
  • We provide a detailed analysis of 20 companies operating in the mica market including Aromax Colourants Pvt.
  • The copper market size is estimated to grow at a CAGR of 6% between 2022 and 2027 with the market size forecast to increase by USD 57.8 billion.

AM Best Once Again Affirms A (Excellent) Rating of Mutual Insurance Company of Arizona

Retrieved on: 
Wednesday, September 6, 2023

PHOENIX, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Today, Mutual Insurance Company of Arizona® (MICA) announced that AM Best has affirmed its Financial Strength Rating (FSR) of A (Excellent) and its Issuer Credit Rating (ICR) of a+ (Excellent) both with a stable outlook.

Key Points: 
  • PHOENIX, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Today, Mutual Insurance Company of Arizona® (MICA) announced that AM Best has affirmed its Financial Strength Rating (FSR) of A (Excellent) and its Issuer Credit Rating (ICR) of a+ (Excellent) both with a stable outlook.
  • MICA Risk Retention Group, Inc. also received a rating of A (Excellent), a+ (Excellent) with a stable outlook.
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .

SightPower awarded MICA funding to develop Automated Mine Shaft Inspection System for Global Mining Industry

Retrieved on: 
Tuesday, September 5, 2023

OTTAWA, ON and SUDBURY, ON, Sept. 5, 2023 /PRNewswire/ - SightPower is excited to announce the awarding of $CAD 612 K funding from the Mining Innovation Commercialization Accelerator (MICA) for the development of an Automated Mine Shaft Inspection AI-based system for the global mining industry.

Key Points: 
  • OTTAWA, ON and SUDBURY, ON, Sept. 5, 2023 /PRNewswire/ - SightPower is excited to announce the awarding of $CAD 612 K funding from the Mining Innovation Commercialization Accelerator (MICA) for the development of an Automated Mine Shaft Inspection AI-based system for the global mining industry.
  • SightPower Inc. offers stakeholders holistic technology for the digital transformation of a mining enterprise with seamless integration of mining data.
  • The project supported by MICA and undertaken by SightPower will bring to industry a unique technological solution for mineshaft inspection.
  • The AI driven, automated shaft monitoring system offers significantly better accuracy and reliability than what can be achieved by an inspection done by a person.

Soil's Breakthrough: DeFi Protocol's Business Model Validated by Local Financial Regulator

Retrieved on: 
Monday, June 26, 2023

Estonia, Tallinn, June 26, 2023 – Soil , the innovative blockchain-based lending protocol, announces that it has received confirmation from the local financial markets regulator that the planned operations on the Soil Platform are compliant with the jurisdiction's regulations.

Key Points: 
  • Estonia, Tallinn, June 26, 2023 – Soil , the innovative blockchain-based lending protocol, announces that it has received confirmation from the local financial markets regulator that the planned operations on the Soil Platform are compliant with the jurisdiction's regulations.
  • This confirmation is a significant milestone for Soil, as it confirms the validity of its business model assumptions.
  • Soil is building a self-balancing DeFi protocol that will bridge the gap between borrowers (traditional businesses / private debt founds) and lenders (stablecoin holders).
  • With an innovative business model and solid legal support, Soil is well-positioned to launch an innovative lending system.

Government of Canada announces the next projects to be funded by the Mining Innovation Commercialization Accelerator Network

Retrieved on: 
Thursday, June 22, 2023

That is why the Government of Canada is investing in innovative mining solutions that will better equip Canada's mining sector to become a major industrial player in the new green economy.

Key Points: 
  • That is why the Government of Canada is investing in innovative mining solutions that will better equip Canada's mining sector to become a major industrial player in the new green economy.
  • Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced the 24 recipients of support selected through the Mining Innovation Commercialization Accelerator (MICA) Network's second call for proposals.
  • MICA's second call for proposals invited applicants to submit projects that will position Canada as a global leader in mining innovation by accelerating the commercialization of made-in-Canada groundbreaking technologies.
  • The Strategic Innovation Fund has provided MICA $40 million to date to support projects for the development and commercialization of new mining technologies.

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors. Findings from the clinical trial will be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the “Developmental Therapeutics—Immunotherapy” session (poster # 2532) on June 3, 2023 from 8:00 AM-11:00 AM Central Time. CLN-619 is being studied in an ongoing Phase 1 clinical trial both as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.

Key Points: 
  • "We are encouraged by the first clinical data for CLN-619 monotherapy, which demonstrates broad potential across a range of tumor types.
  • “Notably, clinical activity was observed in multiple gynecologic cancer types of high unmet need.
  • Based on these initial efficacy observations, we will initiate expansion cohorts in endometrial and cervical cancer and look to expand in additional tumor-specific cohorts as the data matures.
  • Consistent with prespecified criteria and based on initial safety and efficacy observations, Cullinan will initiate monotherapy expansion cohorts in endometrial cancer and cervical cancer.